Sabril Benefits In Infantile Spasms Outweigh Risk Of Vision Loss, Advisory Committee Says

Ovation anti-epileptic gains second unanimous approval recommendation from FDA committee; limited clinical data on vision loss means post-market studies are likely.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet